|
|
|
|
19/09/2024
|
|
|
Marie Skłodowska-Curie Actions
Newsletter
|
|
|
|
|
|
|
|
40 years of EU Research and Innovation
|
|
Celebrating 40 years of EU Research and Innovation with MSCA
|
2024 marks 40 years since the launch of the EU's first funding programme dedicated to science, research and innovation. Over the last four decades, scientists, researchers and innovators have helped the EU maintain its competitive edge in the global economy. Learn how the Marie Skłodowska-Curie Actions (MSCA) have helped brilliant researchers develop their skills and achieve scientific breakthroughs, including 18 Nobel Prize laureate and 3 winners of the European Prize for Women Innovators.
|
|
|
|
|
|
|
|
|
|
MSCA funding
|
|
|
|
|
New MSCA Staff Exchanges co-funding scheme for Indian CSIR organisations
|
The Commission and the Indian Council of Scientific and Industrial Research (CSIR) have started a new co-funding initiative for MSCA Staff Exchanges. The CSIR will top up selected MSCA Staff Exchanges projects, enabling its institutes, laboratories and innovation units to carry out joint research projects with European and international partners. The co-funding will allow them to second their staff to European research organisations for training, skills and career development and knowledge sharing.
|
|
|
|
|
|
|
|
|
Doctoral Networks and COFUND 2024 calls closing soon
|
Submit your proposal for MSCA Doctoral Networks and COFUND doctoral and postdoctoral programmes as early as possible before the deadline expires to avoid last-minute problems.
Check the guidance and handbooks for applicants by MSCA National Contact Points to fine-tune your proposal.
|
|
|
|
|
|
|
|
|
MSCA News
|
|
MSCA receives record receives record number of 10,360 proposals for Postdoctoral Fellowships
|
The fourth call of the Marie Skłodowska-Curie Actions-funded Postdoctoral Fellowships, part of the EU’s Research and Innovation framework programme Horizon Europe, received 10,360 proposals. By comparison, 8,039 proposals were submitted in 2023. This represents an increase of 29%. The European Commission is expected to fund about 1,700 projects, with an indicative budget of €417.2 million. This represents an increase of 60% of the budget compared to the last call.
|
|
|
|
|
|
|
|
|
Apply now to attend the Lindau Nobel Laureate Meetings on chemistry and economic sciences
|
The European Commission is giving current and past Marie Skłodowska-Curie Actions fellows the opportunity to attend the next Lindau meeting on chemistry in summer 2025. About 600 young scientists from all over the world will get the chance to spend an inspiring week with Nobel Laureates to exchange experiences and establish valuable contacts.
|
|
|
|
|
|
|
|
|
Showcase your research at Science is Wonderful! 2025
|
Are you a MSCA fellow or alumni passionate about your work? Ready to share it with the world? We have the best audience queuing up to see you: thousands of primary and secondary school pupils from across Belgium will be traveling to Brussels in March 2025 to visit our Science is Wonderful! science fair. We will pull them into the world of research through live experiments, games and any innovative format you can think of. Be prepared for younger and older pupils, for English, Dutch and French-speaking pupils, and for lots of unexpected questions.
|
|
|
|
|
|
|
|
|
|
Survey: share your best practice examples on supervision under MSCA
|
The Commission has published a survey to gather inspirational examples of good supervision practice from across the MSCA community. The survey is targeted to researchers, supervisors and research staff who have been involved in MSCA projects. Selected stories will be featured on an evidence-based guidance document that will support the existing MSCA guidelines on supervision, while others will be used as case studies in training and promotion..
|
|
|
|
|
|
|
|
|
|
Resources and others
|
|
|
Events
|
|
|
Other funding opportunities and prizes
|
|
|
MSCA Stories
|
|
Podcast: A new age of personalised treatment for prostate cancer
|
|
Computational power, AI, genomics: the treatment and diagnosis of prostate cancer is advancing rapidly. A leap forward in the diagnosis and treatment would be very welcome: prostate cancer is the second most frequent malignancy in men. In 2020 alone, around one and a half million new cases and almost half a million deaths were registered worldwide. The chances of survival depend on the timing of the diagnosis: almost half those diagnosed will survive their prostate cancer for five years or more if it is caught at an early stage. On the occasion of the upcoming World Cancer Research Day, find out how MSCA researchers Dr Joaquin Mateo and Dr Harald Mischak are identifying the most appropriate therapeutic targets and drugs and developing novel forms of precision medicine for this type of cancer.
|
|
|
|
Nanotech oxygen to help phototherapy fight tumours
|
|
Tending to wounded soldiers of the Crimean War, pioneering nurse Florence Nightingale famously described fresh air and light as essential tools for improving hygiene and reducing infection. Today, oxygen and light are once again playing a key role in medicine, this time in the fight against cancers. Photodynamic therapy (PDT) combines light with an organic light-sensitive molecule called a photosensitiser. “When photosensitisers are administrated to a tumour and irradiated with light, they transfer energy to oxygen,” explains MSCA researcher Sergio Moya. “This can induce a series of reactions that cause the destruction of malignant cells and activate the immune system.” These events can lead to the tumour’s eradication.
|
|
|
|
|
|
|
|
You can unsubscribe on your profile page
|
The European Commission is committed to personal data protection. Any personal data is processed in line with the Regulation (EU) 2018/1725. Please read the privacy statement.
|
ISSN: 2600-3201
|
|
|
|